Efficacy and safety of Everolimus in children with TSC - associated epilepsy – Pilot data from an open single-center prospective study

BACKGROUND: Epilepsy occurs in up to 90 % of all individuals with tuberous sclerosis complex (TSC). In 67 % disease onset is during childhood. In ≥ 50 % seizures are refractory to currently available treatment options. The mTOR-Inhibitor Everolimus (Votubia®) was approved for the treatment of subepe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Orphanet J Rare Dis
Main Authors: Samueli, Sharon, Abraham, Klaus, Dressler, Anastasia, Gröppel, Gudrun, Mühlebner-Fahrngruber, Angelika, Scholl, Theresa, Kasprian, Gregor, Laccone, Franco, Feucht, Martha
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5094073/
https://ncbi.nlm.nih.gov/pubmed/27809914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-016-0530-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados